Buruli Ulcer: A Review
DOI:
https://doi.org/10.12970/2310-998X.2014.02.02.5Keywords:
Buruli ulcer, Bairnsdale ulcer, Daintree ulcer, Mycobacterium ulcerans, tropical diseases, infectious diseasesAbstract
Buruli ulcer (BU) is a severe necrotizing infection of skin and soft tissues caused by the fresh-water mycobacterium, Mycobacterium ulcerans. While it is rarely fatal, it can profoundly debilitate those it affects, resulting in extreme individual morbidity, as well as a profound financial, emotional and social burden for the families and communities affected. This review of Buruli ulcer details the history, pathogenesis, diagnosis and management of this neglected tropical disease.
References
Clancey J. Mycobacterial skin ulcers in Uganda. Lancet 1961; 2: 951-4. http://dx.doi.org/10.1016/S0140-6736(61)90793-0
Merritt RW, Walker DE, Small PLC, et al. Ecology and Transmission of Buruli Ulcer Disease: A Systematic Review. PLoS Negl Trop Dis 2010; 4(12): e911. http://dx.doi.org/10.1371/journal.pntd.0000911
WHO, Buruli Ulcer: Progress Report 2004-2008. Wkly Epidemiol Rec 2008; 83: 145-154.
Yotsu RR, Nakanaga K, Hoshino Y, Suzuki K, Ishii N. Buruli ulcer and current situation in Japan: a new emerging cutaneous Mycobacterium infection. J Dermatol 2012; 39(7): 587-93. http://dx.doi.org/10.1111/j.1346-8138.2012.01543.x
Veitch MG, Johnson PD, Flood PE, Leslie DE, Street AC, Hayman JA. A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect 2007; 119(3): 313-8. http://dx.doi.org/10.1017/S0950268897008273
Silva MT, Portaels F, Pedrosa J. Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerands leading to Buruli ulcer. Lancet Infect Dis 2009; 9(11): 699-710. http://dx.doi.org/10.1016/S1473-3099(09)70234-8
George KM, PL, Welty DM, Small PL. Mycobacterium ulcerands toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 2000; 68(2): 877-83. http://dx.doi.org/10.1128/IAI.68.2.877-883.2000
Xing Y, Hande SM, Kishi Y. Photochemistry of mycolactone a/b, the causative toxin of buruli ulcer. J Am Chem Soc 2012; 134(46): 19234-9. http://dx.doi.org/10.1021/ja309215m
Marion E, Song OR, Christophe T, et al. Mycobacterial toxin induces analgesia in buruli ulcer by targeting the Angiotensin pathways. Cell 2014; 157(7): 1565-76. http://dx.doi.org/10.1016/j.cell.2014.04.040
Gryseels S, Amissah D, Durnez L, et al. Amoebae as potential environmental hosts for Mycobacterium ulcerans and other mycobacteria, but doubtful actors in Buruli ulcer epidemiology. PLoS neglect Trop Dis 2012; 6(8): e1764.
Ebong SM, Eyangoh S, Marion E, et al. Survey of water bugs in Bankim, a new buruli ulcer endemic area in Cameroon. J Top Med 2012; 2012: 8.
Gamboa M, Kimbirauskas RK, Merritt RW, Monaghan MT. A molecular approach to identifying the natural prey of the African creeping water bug Naucoris, a potential reservoir of Mycobacterium ulcerans. J Insect Sci 2012; 12: 2. http://dx.doi.org/10.1673/031.012.0201
Lavender CJ, Fyfe JA, Azuolas J, et al. Risk of Buruli ulcer and detection of Mycobacterium ulcerans in mosquitoes in southeastern Australia. PLoS Neglet Trop Dis 2011; 5(9): e1305. http://dx.doi.org/10.1371/journal.pntd.0001305
Stienstra Y, van der Graaf WT, te Meerman GJ, The TH, de Leij LF, van der Werf TS. Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health 2001; 6(7): 554-62. http://dx.doi.org/10.1046/j.1365-3156.2001.00746.x
Ackumey MM, GM, Pappoe M, Kwakye-Maclean C, Weiss MG. Illness meanings and experiences for pre-ulcer and ulcer conditions of Buruli ulcer in the Ga-West and Ga-South Municipalities of Ghana. BMC Public Health 2012; 12: 264. http://dx.doi.org/10.1186/1471-2458-12-264
Onoe H, Yotsu RR, Nakanaga K, Hoshino Y, Ishii N, Takeuchi T. Buruli ulcer accompanied by pain in a Japanese patient. J Dermatol 2012; 39(10): 869-70. http://dx.doi.org/10.1111/j.1346-8138.2011.01430.x
Agbenorku P, Edusei A, Agbenorku M, et al. Buruli-ulcer induced disability in ghana: a study at apromase in the ashanti region. Plast Surg Int 2012; 2012: 752749.
Zavattaro E, Boccafoschi F, Borgogna C, et al. Apoptosis in Buruli ulcer: a clinicopathological study of 45 cases. Histopathology 2012; 61(2): 224-36. http://dx.doi.org/10.1111/j.1365-2559.2012.04206.x
Pahlevan AA, WD, Andrews C, George KM, Small PL, Foxwell BM. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 1999; 163(7): 3928-35.
Martins TG, Fraga AG, Gama JB, et al. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine mycobacterium ulcerans infection. PLoS Negl Trop Dis 2012; 6(11): e1925.
Christinet V, RK, Serafini M, et al. Impact of HIV on Severity of Buruli Ulcer Disease: Results of a retrospective study in Cameroon. Open Forum Infect Dis 2014; 16.
Johnson RC, Nackers F, Glynn JR, et al. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS 2008; 22(7): 901-3. http://dx.doi.org/10.1097/QAD.0b013e3282f7690a
Nienhuis WA, Abass KM, Tuah W, et al. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis 2012; 54(4): 519-26. http://dx.doi.org/10.1093/cid/cir856
World Health Organization. Guidance on sampling techniques for laboratory-confirmation of Mycobacterium ulcerans infection (Buruli ulcer disease). http://www.who.int/ buruli/Guidance_sampling_techniques_MU_infection.pdf?ua=1. (accessed October 5, 2014)
Williamson H, Phillips R, Sarfo S, Wansbrough-Jones M, Small P. Genetic diversity of PCR-positive, culture-negative and culture-positive mycobacterium ulcerans isolated from buruli ulcer patients in Ghana. PLoS One 2014; 9(2): e88007. http://dx.doi.org/10.1371/journal.pone.0088007
Leigheb G, Zavattaro E, Molicotti P, et al. Clinical considerations on Buruli ulcer employing two molecular tests for the detection of Mycobacterium ulcerans in 100 skin biopsies. Int J Dermatol 2014; 53(2): 213-20. http://dx.doi.org/10.1111/ijd.12249
Ruf MT, Schütte D, Chauffour A, Jarlier V, Ji B, Pluschke G. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model. Antimicrob Agents Chem 2012; 56(2): 687-96. http://dx.doi.org/10.1128/AAC.05543-11
Fraga AG, Martins TG, Torrado E, et al. Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination. PLos One 2012; 7(3): 33406. http://dx.doi.org/10.1371/journal.pone.0033406
Agbenorku P, Donwi IK, Kuadzi P, Saunderson P. Buruli ulcer: treatment challenges at three centres in Ghana. J Tropical Med 2012; 2012: 371915. http://dx.doi.org/10.1155/2012/371915
Barimah KB, Mensah J. Ghana’s national health insurance scheme: Insights from members, administrators, and health care providers. J Health Care Poor Underserved 2013; 24(3): 1378-90. http://dx.doi.org/10.1353/hpu.2013.0144
World Health Organizaion. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. World Health Organization 2012.
Nienhuis WA, Thompson WA, Awuah PC, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375(9715): 664-72. http://dx.doi.org/10.1016/S0140-6736(09)61962-0
O'Brien DP, Robson M, Friedman ND, et al. Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis 2013; 13: 416. http://dx.doi.org/10.1186/1471-2334-13-416
Bertolotti A, Izzo A, Grigolato PG, Iabichella ML. The use of ozone therapy in Buruli ulcer had an excellent outcome. BMJ Case Rep 2013.
